1 | placebo-controlled | 16,298 |
2 | parallel-group | 2,274 |
3 | active-controlled | 412 |
4 | sham-controlled | 359 |
5 | parallel-arm | 133 |
6 | non-comparative | 112 |
7 | vehicle-controlled | 110 |
8 | parallel-design | 90 |
9 | nonblind | 66 |
10 | comparator-controlled | 52 |
11 | active-comparator | 50 |
12 | blinded-endpoint | 33 |
13 | parallel-controlled | 32 |
14 | positive-controlled | 29 |
15 | random-assignment | 18 |
16 | dose-controlled | 16 |
17 | placebocontrolled | 14 |
18 | openlabel | 13 |
19 | drug-controlled | 11 |
20 | registrational | 11 |
21 | monocentre | 9 |
22 | treatment-controlled | 9 |
23 | double-arm | 8 |
24 | finher | 8 |
25 | laboratory-blinded | 8 |
26 | six-way | 8 |
27 | triple-dummy | 8 |
28 | controlled-feeding | 7 |
29 | fully-liquid | 7 |
30 | repair-ami | 7 |
31 | single-cohort | 7 |
32 | attention-controlled | 6 |
33 | dose-comparison | 6 |
34 | sorce | 6 |
35 | waitlist-controlled | 6 |
36 | admiral | 5 |
37 | baseline-controlled | 5 |
38 | group-comparative | 5 |
39 | multivendor | 5 |
40 | parallel-assignment | 5 |
41 | single-brushing | 5 |
42 | single-crossover | 5 |
43 | six-sequence | 5 |
44 | three-cell | 5 |
45 | blinded-end-point | 4 |
46 | contralateral-eye | 4 |
47 | gabi | 4 |
48 | methodologically-sound | 4 |
49 | prospective-controlled | 4 |
50 | therapy-controlled | 4 |
51 | aspirin-controlled | 3 |
52 | baataf | 3 |
53 | doubled-blinded | 3 |
54 | eurtac | 3 |
55 | flexible-dosed | 3 |
56 | non-icelandic | 3 |
57 | pl-controlled | 3 |
58 | placebo/active-controlled | 3 |
59 | re-novate® | 3 |
60 | reviewer-blinded | 3 |
61 | saline-controlled | 3 |
62 | superiority-controlled | 3 |
63 | titration-to-goal | 3 |
64 | auo-ab05/95 | 2 |
65 | blinded-endpoints | 2 |
66 | blinded-outcome | 2 |
67 | campus-wide | 2 |
68 | clozapine-refractory | 2 |
69 | clustered-randomised | 2 |
70 | controlled-comparison | 2 |
71 | cost-of-care | 2 |
72 | diclofenac-controlled | 2 |
73 | dose-rising | 2 |
74 | double-placebo-controlled | 2 |
75 | drb1 | 2 |
76 | estrogen-controlled | 2 |
77 | eye-to-eye | 2 |
78 | fellow-eye-controlled | 2 |
79 | fix-dosed | 2 |
80 | forced-dose-escalation | 2 |
81 | gepar-duo | 2 |
82 | good-clinical-practice | 2 |
83 | graded-dose | 2 |
84 | half-head | 2 |
85 | hca-7 | 2 |
86 | lorazepam-controlled | 2 |
87 | maverick | 2 |
88 | multi-herd | 2 |
89 | multiinvestigator | 2 |
90 | non-specialty | 2 |
91 | nontetrazole | 2 |
92 | off-on-off-on | 2 |
93 | open-blind | 2 |
94 | open-controlled | 2 |
95 | optional-titration | 2 |
96 | parallel-comparison | 2 |
97 | parallel-dose | 2 |
98 | parallel-treatment | 2 |
99 | pglyrp2 | 2 |
100 | placebo-controled | 2 |
101 | placebo-masked | 2 |
102 | prompted-titration | 2 |
103 | reannealing | 2 |
104 | sham-acupuncture-controlled | 2 |
105 | split-faced | 2 |
106 | third-party-blinded | 2 |
107 | two-formulation | 2 |
108 | waived-consent | 2 |
109 | well-concealed | 2 |
110 | years.one | 2 |
111 | 1,792-patient | 1 |
112 | 10-armed | 1 |
113 | 12,532 | 1 |
114 | 19-site | 1 |
115 | 192-week | 1 |
116 | 2-parallel-group | 1 |
117 | 20-infusion | 1 |
118 | 2015-the | 1 |
119 | 24-week-fixed-dose | 1 |
120 | 4-to-8-week | 1 |
121 | 41-randomized | 1 |
122 | 47-patient | 1 |
123 | 59-patient | 1 |
124 | 69-center | 1 |
125 | 8974 | 1 |
126 | 9-country | 1 |
127 | 92,834 | 1 |
128 | aba-design | 1 |
129 | abciximab-controlled | 1 |
130 | access-eu | 1 |
131 | acei-1 | 1 |
132 | active-/placebo-controlled | 1 |
133 | adaptive-design | 1 |
134 | advance-1 | 1 |
135 | agar-cloned | 1 |
136 | age-deescalating | 1 |
137 | alfin | 1 |
138 | allopurinol-controlled | 1 |
139 | angra | 1 |
140 | attention-placebo-controlled | 1 |
141 | balanced-crossover | 1 |
142 | bayesian-designed | 1 |
143 | biopsy-controlled | 1 |
144 | bprs-based | 1 |
145 | captopril-controlled | 1 |
146 | casco | 1 |
147 | center-dependent | 1 |
148 | citalopram-controlled | 1 |
149 | clinical-epidemiology-based | 1 |
150 | clinical-outcome | 1 |
151 | clusterrandomized | 1 |
152 | colaus | 1 |
153 | colposcopyc | 1 |
154 | controlled-cohort | 1 |
155 | controlled-parallel | 1 |
156 | controlled-pilot | 1 |
157 | crossover-feeding | 1 |
158 | demonstration-of-concept | 1 |
159 | dental-examiner-masked | 1 |
160 | dhypp | 1 |
161 | dicer-pten | 1 |
162 | diet-and-placebo-controlled | 1 |
163 | diet-evaluation | 1 |
164 | distractor-repeat | 1 |
165 | dose-exploring | 1 |
166 | double-controlled | 1 |
167 | double-titration | 1 |
168 | drug/placebo-drug | 1 |
169 | dual-dose | 1 |
170 | early-entry | 1 |
171 | effects-of-food | 1 |
172 | eight-group | 1 |
173 | embase-unique | 1 |
174 | expert-developed | 1 |
175 | farmer-recorded | 1 |
176 | fesoterodine-controlled | 1 |
177 | ffcd-sfro | 1 |
178 | fixed/flexible-dose | 1 |
179 | forcedtitration | 1 |
180 | four-block | 1 |
181 | fourth-phase | 1 |
182 | full-randomized | 1 |
183 | hours.one | 1 |
184 | hybrid-designed | 1 |
185 | ignored-repetition | 1 |
186 | levodopa-controlled | 1 |
187 | maintenance-of-analgesia | 1 |
188 | mesalamine-controlled | 1 |
189 | mixed-method-design | 1 |
190 | monadic | 1 |
191 | more-definitive | 1 |
192 | mtx-controlled | 1 |
193 | multi-attack | 1 |
194 | multihospital-based | 1 |
195 | multiple-cohort | 1 |
196 | multiple-user | 1 |
197 | multiply-blinded | 1 |
198 | nci-pdq | 1 |
199 | near-all-comer | 1 |
200 | non-case-controlled | 1 |
201 | non-heterogeneous | 1 |
202 | noncross-over | 1 |
203 | nonreceiving | 1 |
204 | nonrigorous | 1 |
205 | nonstrategy | 1 |
206 | olanzapine-comparator | 1 |
207 | one-label | 1 |
208 | one-way-crossover | 1 |
209 | opc-based | 1 |
210 | open-randomized | 1 |
211 | opla-controlled | 1 |
212 | ovid-currents | 1 |
213 | parallel-armed | 1 |
214 | parallel-group/crossover | 1 |
215 | parallel-intervention | 1 |
216 | partial-crossover | 1 |
217 | partially-inpatient | 1 |
218 | peer-implemented | 1 |
219 | petrolatum-controlled | 1 |
220 | phase-2a | 1 |
221 | phase-i/ii | 1 |
222 | physician-blinded | 1 |
223 | place-bo-controlled | 1 |
224 | placebo-con | 1 |
225 | placebo-contralaterally-controlled | 1 |
226 | placebo-crossover | 1 |
227 | placebo-parallel-controlled | 1 |
228 | placebo/controlled | 1 |
229 | plc-controlled | 1 |
230 | positive-drug | 1 |
231 | pouchitis.a | 1 |
232 | ppar-2 | 1 |
233 | quasi-effectiveness | 1 |
234 | randomize-controlled | 1 |
235 | randomized-parallel | 1 |
236 | randomized-start | 1 |
237 | route-comparison | 1 |
238 | safety-assessor-blinded | 1 |
239 | semenogram | 1 |
240 | seretide-controlled | 1 |
241 | sham-stimulation-controlled | 1 |
242 | simulated-injection | 1 |
243 | single-/multi-center | 1 |
244 | single-controlled | 1 |
245 | single-dose-escalation | 1 |
246 | single-rising-dose | 1 |
247 | single-risk-factor | 1 |
248 | sirocco | 1 |
249 | six-arm | 1 |
250 | socioconstructivist | 1 |
251 | standard-controlled | 1 |
252 | survival-analysis-based | 1 |
253 | t1c-t2 | 1 |
254 | tb-prevention | 1 |
255 | tightly-controlled | 1 |
256 | timi-30 | 1 |
257 | tnni3k/csq | 1 |
258 | tryphaena | 1 |
259 | turneffe | 1 |
260 | two-dosage-controlled | 1 |
261 | well-built | 1 |
262 | within-between-subjects | 1 |
263 | wl-controlled | 1 |
1 | 1,792-patient | 1 |
2 | 10-armed | 1 |
3 | 12,532 | 1 |
4 | 19-site | 1 |
5 | 192-week | 1 |
6 | 2-parallel-group | 1 |
7 | 20-infusion | 1 |
8 | 2015-the | 1 |
9 | 24-week-fixed-dose | 1 |
10 | 4-to-8-week | 1 |
11 | 41-randomized | 1 |
12 | 47-patient | 1 |
13 | 59-patient | 1 |
14 | 69-center | 1 |
15 | 8974 | 1 |
16 | 9-country | 1 |
17 | 92,834 | 1 |
18 | aba-design | 1 |
19 | abciximab-controlled | 1 |
20 | access-eu | 1 |
21 | acei-1 | 1 |
22 | active-/placebo-controlled | 1 |
23 | active-comparator | 50 |
24 | active-controlled | 412 |
25 | adaptive-design | 1 |
26 | admiral | 5 |
27 | advance-1 | 1 |
28 | agar-cloned | 1 |
29 | age-deescalating | 1 |
30 | alfin | 1 |
31 | allopurinol-controlled | 1 |
32 | angra | 1 |
33 | aspirin-controlled | 3 |
34 | attention-controlled | 6 |
35 | attention-placebo-controlled | 1 |
36 | auo-ab05/95 | 2 |
37 | baataf | 3 |
38 | balanced-crossover | 1 |
39 | baseline-controlled | 5 |
40 | bayesian-designed | 1 |
41 | biopsy-controlled | 1 |
42 | blinded-end-point | 4 |
43 | blinded-endpoint | 33 |
44 | blinded-endpoints | 2 |
45 | blinded-outcome | 2 |
46 | bprs-based | 1 |
47 | campus-wide | 2 |
48 | captopril-controlled | 1 |
49 | casco | 1 |
50 | center-dependent | 1 |
51 | citalopram-controlled | 1 |
52 | clinical-epidemiology-based | 1 |
53 | clinical-outcome | 1 |
54 | clozapine-refractory | 2 |
55 | clustered-randomised | 2 |
56 | clusterrandomized | 1 |
57 | colaus | 1 |
58 | colposcopyc | 1 |
59 | comparator-controlled | 52 |
60 | contralateral-eye | 4 |
61 | controlled-cohort | 1 |
62 | controlled-comparison | 2 |
63 | controlled-feeding | 7 |
64 | controlled-parallel | 1 |
65 | controlled-pilot | 1 |
66 | cost-of-care | 2 |
67 | crossover-feeding | 1 |
68 | demonstration-of-concept | 1 |
69 | dental-examiner-masked | 1 |
70 | dhypp | 1 |
71 | dicer-pten | 1 |
72 | diclofenac-controlled | 2 |
73 | diet-and-placebo-controlled | 1 |
74 | diet-evaluation | 1 |
75 | distractor-repeat | 1 |
76 | dose-comparison | 6 |
77 | dose-controlled | 16 |
78 | dose-exploring | 1 |
79 | dose-rising | 2 |
80 | double-arm | 8 |
81 | double-controlled | 1 |
82 | double-placebo-controlled | 2 |
83 | double-titration | 1 |
84 | doubled-blinded | 3 |
85 | drb1 | 2 |
86 | drug-controlled | 11 |
87 | drug/placebo-drug | 1 |
88 | dual-dose | 1 |
89 | early-entry | 1 |
90 | effects-of-food | 1 |
91 | eight-group | 1 |
92 | embase-unique | 1 |
93 | estrogen-controlled | 2 |
94 | eurtac | 3 |
95 | expert-developed | 1 |
96 | eye-to-eye | 2 |
97 | farmer-recorded | 1 |
98 | fellow-eye-controlled | 2 |
99 | fesoterodine-controlled | 1 |
100 | ffcd-sfro | 1 |
101 | finher | 8 |
102 | fix-dosed | 2 |
103 | fixed/flexible-dose | 1 |
104 | flexible-dosed | 3 |
105 | forced-dose-escalation | 2 |
106 | forcedtitration | 1 |
107 | four-block | 1 |
108 | fourth-phase | 1 |
109 | full-randomized | 1 |
110 | fully-liquid | 7 |
111 | gabi | 4 |
112 | gepar-duo | 2 |
113 | good-clinical-practice | 2 |
114 | graded-dose | 2 |
115 | group-comparative | 5 |
116 | half-head | 2 |
117 | hca-7 | 2 |
118 | hours.one | 1 |
119 | hybrid-designed | 1 |
120 | ignored-repetition | 1 |
121 | laboratory-blinded | 8 |
122 | levodopa-controlled | 1 |
123 | lorazepam-controlled | 2 |
124 | maintenance-of-analgesia | 1 |
125 | maverick | 2 |
126 | mesalamine-controlled | 1 |
127 | methodologically-sound | 4 |
128 | mixed-method-design | 1 |
129 | monadic | 1 |
130 | monocentre | 9 |
131 | more-definitive | 1 |
132 | mtx-controlled | 1 |
133 | multi-attack | 1 |
134 | multi-herd | 2 |
135 | multihospital-based | 1 |
136 | multiinvestigator | 2 |
137 | multiple-cohort | 1 |
138 | multiple-user | 1 |
139 | multiply-blinded | 1 |
140 | multivendor | 5 |
141 | nci-pdq | 1 |
142 | near-all-comer | 1 |
143 | non-case-controlled | 1 |
144 | non-comparative | 112 |
145 | non-heterogeneous | 1 |
146 | non-icelandic | 3 |
147 | non-specialty | 2 |
148 | nonblind | 66 |
149 | noncross-over | 1 |
150 | nonreceiving | 1 |
151 | nonrigorous | 1 |
152 | nonstrategy | 1 |
153 | nontetrazole | 2 |
154 | off-on-off-on | 2 |
155 | olanzapine-comparator | 1 |
156 | one-label | 1 |
157 | one-way-crossover | 1 |
158 | opc-based | 1 |
159 | open-blind | 2 |
160 | open-controlled | 2 |
161 | open-randomized | 1 |
162 | openlabel | 13 |
163 | opla-controlled | 1 |
164 | optional-titration | 2 |
165 | ovid-currents | 1 |
166 | parallel-arm | 133 |
167 | parallel-armed | 1 |
168 | parallel-assignment | 5 |
169 | parallel-comparison | 2 |
170 | parallel-controlled | 32 |
171 | parallel-design | 90 |
172 | parallel-dose | 2 |
173 | parallel-group | 2,274 |
174 | parallel-group/crossover | 1 |
175 | parallel-intervention | 1 |
176 | parallel-treatment | 2 |
177 | partial-crossover | 1 |
178 | partially-inpatient | 1 |
179 | peer-implemented | 1 |
180 | petrolatum-controlled | 1 |
181 | pglyrp2 | 2 |
182 | phase-2a | 1 |
183 | phase-i/ii | 1 |
184 | physician-blinded | 1 |
185 | pl-controlled | 3 |
186 | place-bo-controlled | 1 |
187 | placebo-con | 1 |
188 | placebo-contralaterally-controlled | 1 |
189 | placebo-controled | 2 |
190 | placebo-controlled | 16,298 |
191 | placebo-crossover | 1 |
192 | placebo-masked | 2 |
193 | placebo-parallel-controlled | 1 |
194 | placebo/active-controlled | 3 |
195 | placebo/controlled | 1 |
196 | placebocontrolled | 14 |
197 | plc-controlled | 1 |
198 | positive-controlled | 29 |
199 | positive-drug | 1 |
200 | pouchitis.a | 1 |
201 | ppar-2 | 1 |
202 | prompted-titration | 2 |
203 | prospective-controlled | 4 |
204 | quasi-effectiveness | 1 |
205 | random-assignment | 18 |
206 | randomize-controlled | 1 |
207 | randomized-parallel | 1 |
208 | randomized-start | 1 |
209 | re-novate® | 3 |
210 | reannealing | 2 |
211 | registrational | 11 |
212 | repair-ami | 7 |
213 | reviewer-blinded | 3 |
214 | route-comparison | 1 |
215 | safety-assessor-blinded | 1 |
216 | saline-controlled | 3 |
217 | semenogram | 1 |
218 | seretide-controlled | 1 |
219 | sham-acupuncture-controlled | 2 |
220 | sham-controlled | 359 |
221 | sham-stimulation-controlled | 1 |
222 | simulated-injection | 1 |
223 | single-/multi-center | 1 |
224 | single-brushing | 5 |
225 | single-cohort | 7 |
226 | single-controlled | 1 |
227 | single-crossover | 5 |
228 | single-dose-escalation | 1 |
229 | single-rising-dose | 1 |
230 | single-risk-factor | 1 |
231 | sirocco | 1 |
232 | six-arm | 1 |
233 | six-sequence | 5 |
234 | six-way | 8 |
235 | socioconstructivist | 1 |
236 | sorce | 6 |
237 | split-faced | 2 |
238 | standard-controlled | 1 |
239 | superiority-controlled | 3 |
240 | survival-analysis-based | 1 |
241 | t1c-t2 | 1 |
242 | tb-prevention | 1 |
243 | therapy-controlled | 4 |
244 | third-party-blinded | 2 |
245 | three-cell | 5 |
246 | tightly-controlled | 1 |
247 | timi-30 | 1 |
248 | titration-to-goal | 3 |
249 | tnni3k/csq | 1 |
250 | treatment-controlled | 9 |
251 | triple-dummy | 8 |
252 | tryphaena | 1 |
253 | turneffe | 1 |
254 | two-dosage-controlled | 1 |
255 | two-formulation | 2 |
256 | vehicle-controlled | 110 |
257 | waitlist-controlled | 6 |
258 | waived-consent | 2 |
259 | well-built | 1 |
260 | well-concealed | 2 |
261 | within-between-subjects | 1 |
262 | wl-controlled | 1 |
263 | years.one | 2 |
1 | timi-30 | 1 |
2 | advance-1 | 1 |
3 | acei-1 | 1 |
4 | drb1 | 2 |
5 | ppar-2 | 1 |
6 | 12,532 | 1 |
7 | pglyrp2 | 2 |
8 | t1c-t2 | 1 |
9 | 92,834 | 1 |
10 | 8974 | 1 |
11 | auo-ab05/95 | 2 |
12 | hca-7 | 2 |
13 | pouchitis.a | 1 |
14 | phase-2a | 1 |
15 | maintenance-of-analgesia | 1 |
16 | tryphaena | 1 |
17 | angra | 1 |
18 | eurtac | 3 |
19 | monadic | 1 |
20 | non-icelandic | 3 |
21 | colposcopyc | 1 |
22 | half-head | 2 |
23 | split-faced | 2 |
24 | doubled-blinded | 3 |
25 | physician-blinded | 1 |
26 | reviewer-blinded | 3 |
27 | safety-assessor-blinded | 1 |
28 | multiply-blinded | 1 |
29 | laboratory-blinded | 8 |
30 | third-party-blinded | 2 |
31 | farmer-recorded | 1 |
32 | placebo-masked | 2 |
33 | dental-examiner-masked | 1 |
34 | well-concealed | 2 |
35 | opla-controlled | 1 |
36 | levodopa-controlled | 1 |
37 | abciximab-controlled | 1 |
38 | diclofenac-controlled | 2 |
39 | plc-controlled | 1 |
40 | standard-controlled | 1 |
41 | seretide-controlled | 1 |
42 | two-dosage-controlled | 1 |
43 | double-controlled | 1 |
44 | vehicle-controlled | 110 |
45 | single-controlled | 1 |
46 | fesoterodine-controlled | 1 |
47 | saline-controlled | 3 |
48 | baseline-controlled | 5 |
49 | mesalamine-controlled | 1 |
50 | sham-acupuncture-controlled | 2 |
51 | non-case-controlled | 1 |
52 | dose-controlled | 16 |
53 | active-controlled | 412 |
54 | placebo/active-controlled | 3 |
55 | prospective-controlled | 4 |
56 | positive-controlled | 29 |
57 | fellow-eye-controlled | 2 |
58 | randomize-controlled | 1 |
59 | drug-controlled | 11 |
60 | parallel-controlled | 32 |
61 | placebo-parallel-controlled | 1 |
62 | captopril-controlled | 1 |
63 | allopurinol-controlled | 1 |
64 | pl-controlled | 3 |
65 | wl-controlled | 1 |
66 | sham-controlled | 359 |
67 | lorazepam-controlled | 2 |
68 | citalopram-controlled | 1 |
69 | petrolatum-controlled | 1 |
70 | estrogen-controlled | 2 |
71 | open-controlled | 2 |
72 | aspirin-controlled | 3 |
73 | sham-stimulation-controlled | 1 |
74 | attention-controlled | 6 |
75 | place-bo-controlled | 1 |
76 | placebo-controlled | 16,298 |
77 | diet-and-placebo-controlled | 1 |
78 | double-placebo-controlled | 2 |
79 | attention-placebo-controlled | 1 |
80 | active-/placebo-controlled | 1 |
81 | comparator-controlled | 52 |
82 | treatment-controlled | 9 |
83 | waitlist-controlled | 6 |
84 | mtx-controlled | 1 |
85 | placebo-contralaterally-controlled | 1 |
86 | tightly-controlled | 1 |
87 | therapy-controlled | 4 |
88 | biopsy-controlled | 1 |
89 | superiority-controlled | 3 |
90 | placebo/controlled | 1 |
91 | placebocontrolled | 14 |
92 | placebo-controled | 2 |
93 | 10-armed | 1 |
94 | parallel-armed | 1 |
95 | hybrid-designed | 1 |
96 | bayesian-designed | 1 |
97 | agar-cloned | 1 |
98 | expert-developed | 1 |
99 | opc-based | 1 |
100 | multihospital-based | 1 |
101 | survival-analysis-based | 1 |
102 | bprs-based | 1 |
103 | clinical-epidemiology-based | 1 |
104 | clustered-randomised | 2 |
105 | flexible-dosed | 3 |
106 | fix-dosed | 2 |
107 | peer-implemented | 1 |
108 | 41-randomized | 1 |
109 | full-randomized | 1 |
110 | open-randomized | 1 |
111 | clusterrandomized | 1 |
112 | fully-liquid | 7 |
113 | open-blind | 2 |
114 | nonblind | 66 |
115 | methodologically-sound | 4 |
116 | effects-of-food | 1 |
117 | multi-herd | 2 |
118 | good-clinical-practice | 2 |
119 | six-sequence | 5 |
120 | sorce | 6 |
121 | campus-wide | 2 |
122 | turneffe | 1 |
123 | 2015-the | 1 |
124 | nontetrazole | 2 |
125 | blinded-outcome | 2 |
126 | clinical-outcome | 1 |
127 | years.one | 2 |
128 | hours.one | 1 |
129 | cost-of-care | 2 |
130 | monocentre | 9 |
131 | fourth-phase | 1 |
132 | graded-dose | 2 |
133 | 24-week-fixed-dose | 1 |
134 | fixed/flexible-dose | 1 |
135 | single-rising-dose | 1 |
136 | dual-dose | 1 |
137 | parallel-dose | 2 |
138 | 19-site | 1 |
139 | embase-unique | 1 |
140 | non-comparative | 112 |
141 | group-comparative | 5 |
142 | more-definitive | 1 |
143 | contralateral-eye | 4 |
144 | eye-to-eye | 2 |
145 | baataf | 3 |
146 | controlled-feeding | 7 |
147 | crossover-feeding | 1 |
148 | single-brushing | 5 |
149 | reannealing | 2 |
150 | dose-exploring | 1 |
151 | dose-rising | 2 |
152 | age-deescalating | 1 |
153 | nonreceiving | 1 |
154 | positive-drug | 1 |
155 | drug/placebo-drug | 1 |
156 | gabi | 4 |
157 | phase-i/ii | 1 |
158 | repair-ami | 7 |
159 | multi-attack | 1 |
160 | maverick | 2 |
161 | four-block | 1 |
162 | 192-week | 1 |
163 | 4-to-8-week | 1 |
164 | registrational | 11 |
165 | titration-to-goal | 3 |
166 | admiral | 5 |
167 | one-label | 1 |
168 | openlabel | 13 |
169 | controlled-parallel | 1 |
170 | randomized-parallel | 1 |
171 | three-cell | 5 |
172 | semenogram | 1 |
173 | double-arm | 8 |
174 | parallel-arm | 133 |
175 | six-arm | 1 |
176 | dicer-pten | 1 |
177 | aba-design | 1 |
178 | mixed-method-design | 1 |
179 | adaptive-design | 1 |
180 | parallel-design | 90 |
181 | alfin | 1 |
182 | off-on-off-on | 2 |
183 | placebo-con | 1 |
184 | 20-infusion | 1 |
185 | forced-dose-escalation | 2 |
186 | single-dose-escalation | 1 |
187 | two-formulation | 2 |
188 | prompted-titration | 2 |
189 | double-titration | 1 |
190 | optional-titration | 2 |
191 | forcedtitration | 1 |
192 | diet-evaluation | 1 |
193 | simulated-injection | 1 |
194 | ignored-repetition | 1 |
195 | tb-prevention | 1 |
196 | parallel-intervention | 1 |
197 | controlled-comparison | 2 |
198 | dose-comparison | 6 |
199 | route-comparison | 1 |
200 | parallel-comparison | 2 |
201 | sirocco | 1 |
202 | casco | 1 |
203 | ffcd-sfro | 1 |
204 | gepar-duo | 2 |
205 | dhypp | 1 |
206 | parallel-group | 2,274 |
207 | 2-parallel-group | 1 |
208 | eight-group | 1 |
209 | nci-pdq | 1 |
210 | tnni3k/csq | 1 |
211 | finher | 8 |
212 | near-all-comer | 1 |
213 | multiple-user | 1 |
214 | 69-center | 1 |
215 | single-/multi-center | 1 |
216 | noncross-over | 1 |
217 | balanced-crossover | 1 |
218 | single-crossover | 5 |
219 | partial-crossover | 1 |
220 | placebo-crossover | 1 |
221 | one-way-crossover | 1 |
222 | parallel-group/crossover | 1 |
223 | multivendor | 5 |
224 | multiinvestigator | 2 |
225 | olanzapine-comparator | 1 |
226 | active-comparator | 50 |
227 | single-risk-factor | 1 |
228 | quasi-effectiveness | 1 |
229 | within-between-subjects | 1 |
230 | ovid-currents | 1 |
231 | blinded-endpoints | 2 |
232 | colaus | 1 |
233 | non-heterogeneous | 1 |
234 | nonrigorous | 1 |
235 | distractor-repeat | 1 |
236 | well-built | 1 |
237 | center-dependent | 1 |
238 | 1,792-patient | 1 |
239 | 47-patient | 1 |
240 | 59-patient | 1 |
241 | partially-inpatient | 1 |
242 | parallel-assignment | 5 |
243 | random-assignment | 18 |
244 | parallel-treatment | 2 |
245 | waived-consent | 2 |
246 | blinded-end-point | 4 |
247 | blinded-endpoint | 33 |
248 | controlled-pilot | 1 |
249 | demonstration-of-concept | 1 |
250 | randomized-start | 1 |
251 | controlled-cohort | 1 |
252 | single-cohort | 7 |
253 | multiple-cohort | 1 |
254 | socioconstructivist | 1 |
255 | access-eu | 1 |
256 | six-way | 8 |
257 | nonstrategy | 1 |
258 | triple-dummy | 8 |
259 | clozapine-refractory | 2 |
260 | early-entry | 1 |
261 | 9-country | 1 |
262 | non-specialty | 2 |
263 | re-novate® | 3 |